What Happened?

Will the new Food and Drug Administration (FDA) nominee, Heidi Overton, be politically independent and follow scientific consensus regarding vaccine safety? The Senate hearing for President Trump's pick to lead the FDA turned contentious Thursday as senators pressed her on vaccine safety and whether she would push back against the president on scientific matters.

The FDA oversees the safety of drugs, medical devices, and vaccines used by virtually every American, and the agency has been without a permanent leader since former commissioner Marty Makary resigned in May 2026. Trump nominated Overton in August 2026. Before joining the White House as deputy assistant to the president for domestic policy, she served as chief policy officer at the America First Policy Institute, a conservative think tank.

Why Does it Matter to Me?

The hearing surfaced two specific policy questions with direct consequences for families: vaccine safety and access to mifepristone.

  • Trump signed an executive order seeking to break up the combined measles, mumps, and rubella (MMR) vaccine into three separate shots and reduce the recommended childhood vaccine schedule.
  • The FDA is re-evaluating the safety of mifepristone, a medication used to end pregnancies, following Republican pressure to tighten access, including reversing a rule that allows it to be prescribed via telemedicine and mailed to patients.

Both Sides, Now

Sen. Bill Cassidy (R-LA), a licensed doctor who chairs the Senate Health, Education, Labor, and Pensions Committee (HELP), pressed Overton on whether she would defy the president if ordered to act against her commitments to the committee. Overton told the committee she would "give him my best advice, and I would follow the statutory requirements for the role of FDA commissioners." She affirmed the MMR vaccine is safe and effective, but declined to say whether Trump was wrong when he called the measles vaccine "lethal," saying only that it is "not lethal."

Sen. Bernard Sanders (I-VT) asked whether she would "stand up to somebody who lies all of the time." Sen. Christopher Murphy (D-CT) outlined a timeline alleging political interference involving an $8 million corporate donation, a White House meeting, and an FDA rule change on flavored vapes. Overton responded: "I reject the framing of that question."

The Center for Science in the Public Interest urged the Senate to block her nomination, while Americans United for Life formally endorsed her confirmation.

What Happens Next?

A committee vote must occur before Overton's nomination can advance to the full Senate floor, and no date for either that vote or a full Senate floor vote has been announced.

Cassidy, who lost his Republican primary and will leave the Senate in January, is described by political analysis firm Affinity Strategies as "feeling no pressure to appease the White House." His sustained skepticism puts Overton's path to confirmation in doubt, with one analysis noting she needs every Republican on the panel if all Democrats vote against her.

---

AllCiv makes it easy to stay politically informed and involved.

---

Spot something wrong? Report an issue with this article